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Effects of hydrochlorothiazide on Na-K-ATPase activity along the rat
nephron. Na-K-ATPase activity was determined in seven nephron
segments of five—week—old, spontaneously hypertensive rats (SHR)
with or without continuous hydrochlorothiazide (HCTZ) treatment for
seven days. For comparison, the effects of HCTZ treatment on Na-K-
ATPase activity in the nephron segments of age—matched normotensive
Wistar—Kyoto rats (WKY) were also determined. Na-K-ATPase activ-
ity in proximal convoluted tubule (PCT), medullary thick ascending
limb (MTAL), cortical thick ascending limb (CTAL), distal convoluted
tubule (DCT) and cortical collecting duct (CCD) was significantly lower
in HCTZ-treated SHR compared to control (untreated) SHR. However,
there was no significant difference in Na-K-ATPase activity in proximal
straight tubule (PST) and medullary collecting duct (MCD) between
HCTZ-treated and control SHR. HCTZ treatment also produced a
significant decrease in blood pressure (BP) and creatinine clearance
(Ccr) in SHR. On the other hand, HCTZ treatment did not produce a
significant change in Na-K-ATPase activity in PCT, PST, MTAL,
CTAL and MCD, in BP or in C. in WKY. However, HCTZ treatment
produced a decrease in the enzyme activity in the DCT and an increase
in the enzyme activity in the CCD in WKY. The decrease in Na-K-
ATPase activity in almost all nephron segments from SHR may be due
to a significant decrease in CCr produced by HCTZ. On the other hand,
a decrease in Na-K-ATPase activity in the DCT with an increase in the
enzyme activity in the CCD from WKY suggest that renal compensa-
tion to the natriuretic effect of HCTZ occurs by an increase in Na
reabsorption in the CCD.
Recently, we have reported that there is an abnormal pattern
of Na-K-ATPase activity along the nephron during develop-
ment of hypertension in the spontaneously hypertensive rat
(SHR) [1]. The enzyme activity is higher in proximal tubule
from five—week—old SHR than from age—matched normotensive
Wistar—Kyoto rat (WKY). On the other hand, the enzyme
activity is lower in the thick ascending limb and distal convo-
luted tubule in young SHR than in WKY. This abnormal pattern
of Na-K-ATPase activity along the nephron is also present in
eight—week—old SHR but not in 12-week—old SHR [2, 3].
The purpose of the present study was twofold: a) to deter-
mine if one week treatment of young SHR with hydrochioro-
thiazide (HCTZ) brings Na-K-ATPase activity in various neph-
ron segments of SHR to normal levels, that is, equal to that of
age matched WKY; and b) to determine if the renal compensa-
tion for the natriuretic effect of HCTZ in SHR and WKY occurs
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due to the development of resistance to the action of the drug at
the site of its action, that is, distal convoluted tubule [4—6], or it
occurs due to a compensatory increase in Na reabsorption
beyond the distal convoluted tubule in segments, such as
cortical collecting duct. We have previously reported that there
is a good relationship between net Na reabsorption and
Na-K-ATPase activity in various nephron segments of normal
animals and animals treated chronically with hormones [71.
Therefore, we used Na-K-ATPase activity as an index of net
Na reabsorption in various nephron segments and studied the
effects of one week treatment of young SHR and WKY with
HCTZ on the enzyme activity.
Methods
Animals
Three— to four—week-old male SHR and WKY were obtained
from Charles River Breeding Laboratories (Wilmington, Mas-
sachusetts, USA). The animals of each strain were divided into
two groups: Control and HCTZ-treated group. HCTZ was
administered at a dose of 15 mg/kg body wt/day for seven days
using an osmotic minipump (AIza Corp., Palo Alto, California,
USA) implanted subcutaneously in the neck region of the
animal (under pentobarbital anesthesia). The control animals
were administered vehicle (polyethylene glycol) alone in the
osmotic minipump. All rats were housed in a room with an
ambient temperature of 26°C and a 12-hour light and dark cycle.
The animals were given standard rat chow (Purina—Ralston, St.
Louis, Missouri, USA) and free access to water.
The systolic BP of each rat was measured for 10 days (5 days
before and 5 days after the treatment) by the tail cuff method
described previously [1]. Urine was collected for 24 hours by
placing each rat in a metabolic cage (Nalge, New York, USA)
one day before sacrificing the animal. A blood sample was
collected from each rat (under pentobartibal anesthesia) by
heart puncture on the day of sacrifice.
Microdissection of nephron segments
The individual nephron segments were dissected from
collagenase—treated renal tissue as described previously [7].
The types of microdissected segments and their locations were:
proximal convoluted tubule (PCT) next to glomerulus; proximal
straight tubule (PST) from the cortex; medullary thick ascend-
ing limb (MTAL) from the inner stripe of the outer medulla;
cortical thick ascending limb (CTAL) just before macula densa;
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Table 1. Age, body weight, kidney weight, and blood pressure of
control and HCTZ treated rats
.Rat strain and
treatment N
Age
days
Body
wt, g
.
Kidney
wt, g
BP,m
Initial
mHg
Final
SHR, Control 7 39 1.4 70 5 0.34 0.02 124 4 l32 4
SHR, HCTZ 8 39 1.3 70 5 0.37 0.02 123 2 ll6 4
WKY, Control 6 37 0.3 80 5 0.36 0.01 118 5 121 6
WKY,HCTZ 7 38±0.4 79±4 0.35±0.02 119±3 121±3
HCTZ treatment was given for one week. Each value is mean SE of
N animals.
a p < 0.05 vs. Initial (pretreatment) BP in same animals (as deter-
mined by paired (-test)
cortical collecting duct (CCD) from the medullary ray (Starting
from the junction of two tubules); and medullary collecting duct
(MCD) from the inner stripe of the outer medulla. The length of
each tubule was measured and the tubule was transferred to a
vial where it was given osmotic and temperature shock as
described previously [71.
Assay of Na-K-A TPase
The activity of Na-K-ATPase was determined by a fluoro-
metric method which involves coupling of the hydrolysis of
ATP with oxidation of NADH. The details of the method have
been described previously [7]. Total ATPase activity was
determined in the absence of ouabain and the residual ATPase
(called Mg-ATPase) activity was determined in the presence of
4 m ouabain. The difference between the total and the residual
ATPase activity was called (ouabain—sensitive) Na-K-ATPase
activity.
Analysis of electrolytes
Na and K concentrations in plasma and urine samples
were determined by flame photometry (Instrumentation Labo-
ratory, Model 143, Lexington, Massachusetts, USA). Creati-
nine was determined by the Jaffe's reaction [8].
Statistics
Statistical comparisons between control and HCTZ treated
groups of each strain of animals were made by the Student
unpaired t-test. Where appropriate, comparisons were also
made between SHR and WKY by the unpaired t-test. In
addition, blood pressure comparisons between the pretreatment
and the posttreatment periods for each group of rats were made
by the paired f-test. If the difference between the two means
had a P < 0.05, the values were considered significantly
different from each other.
Results
Body weight, kidney weight and blood pressure of HCTZ
treated and control rats
HCTZ treatment did not produce a significant change in the
body weights or kidney weights of SHR or WKY as compared
to the controls of the same strain (Table 1). Furthermore, there
was no significant difference in the mean body weights of
five—week—old SHR (both HCTZ treated and untreated) and
WKY. The final BP (at the end of 1 week experimental period)
was small (8 mm Hg) but significantly higher than the initial
(before treatment) BP in control SHR, indicating that these
animals had started developing hypertension at this stage.
HCTZ treatment not only prevented the development of hyper-
tension but actually produced a small (7 mm Hg) but significant
decrease in BP in SHR. On the other hand, there was no
significant change in BP of either control or HCTZ-treated
WKY during the experimental period.
Plasma concentration and urinary excretion of Na and K,
and clearance of creatinine in HCTZ treated and control
rats.
The concentration of Na in the plasma was significantly
lower in HCTZ treated SHR compared to control SHR (Table
2). In addition, plasma Na was also lower in control WKY
than in control SHR. Other group comparisons indicated no
significant differences in plasma Nat HCTZ treatment of both
SHR and WKY did not produce a significant decrease in plasma
K concentration. On the other hand, excretion of Na and K
in HCTZ treated WKY was significantly higher than HCTZ
treated SHR, in spite of the fact that there was no difference in
the excretion of Na and K between WKY and SHR controls.
However, the creatinine clearance (Cr) was significantly lower
in HCTZ treated SHR than in control SHR. The decrease in Ccr
by HCTZ in SHR may be responsible for the lack of natriuretic
and kaliuretic effect of this drug in this rat strain. The CCr in
HCTZ treated WKY was not different from that of WKY
control.
Effects of HCTZ treatment on Na-K-A TPase activity in
nephron segments of each rat strain.
Na-K-ATPase activity in the PCT, MTAL, CTAL, DCT and
CCD was significantly lower in HCTZ-treated SHR than in
control SHR (Fig. 1). There was no difference in the enzyme
activity in the PST and MCD between control and HCTZ
treated SHR.
Na-K-ATPase activity was significantly lower in the DCT and
higher in the CCD of HCTZ treated WKY than of control
WKY. There was no significant difference in the enzyme
activity in the PCT, PST, MTAL, CTAL and MCD between
control and HCTZ treated WKY.
Comparison of Na-K-A TPase activity in nephron segments
between two strains (SHR and WKY)
Na-K-ATPase activity was significantly higher in the PCT
and PST and lower in the MTAL and DCT from control SHR
compared to control WKY (Fig. 1). However, there were no
significant differences in the enzyme activity in CTAL, CCD
and MCD between SHR and WKY controls.
Because of a decrease in Na-K-ATPase activity in almost all
nephron segments of SHR treated with HCTZ (Fig. 1), and only
in the DCT in WKY treated with the drug, the enzyme activity
was significantly lower in MTAL, CTAL, DCT and CCD from
HCTZ treated SHR relative to HCTZ treated WKY. However,
there was no difference in Na-K-ATPase activity in PCT, PST
and MCD between HCTZ treated SHR and HCTZ treated
WKY.
920 Garg and Narang
Table 2. Plasma concentration and urinary excretion of Na and K and clearance of creatinine in control and HCTZ treated rats
Rat strain afld
treatment N
PNa
mEqlliter
PK
mEqiliter
UNa
mEq/day
UK V
mEq/day
Ccr
mi/hr
SHR, Control 6—7 150 0.7 4.4 0.2 0.55 0.09 1.5 0.1 10.4 1.5
SHR, HCTZ 5—8 145 l.P 3.9 0.2 0.49 0.05 1.4 0.1 6.5 l.2
WKY, Control 4—5 147 0.5l 4.7 0.2 0.52 0.10 1.9 0.3 9.5 1.4
WKY, HCTZ 7 146 2.5 4.1 0.3 0,79 0,13b 2.4 0,2b 11.0 2.0
HCTZ treatment was given for one week. Each value is mean SE of N animals.
P < 0.05 vs. control rats of same strain
b P < 0.05 vs. rats of different strain given same treatment
Segment
Control
SHR
HCTZ
SHR
Control
WKY
HCTZ
WKY
PCT 43±6 43±4 50±2 51±6
PST 24±2 25±2 27±2 33±3
MTAL 41±4 44±4 43±4 45±4
CTAL 37±3 35±3 44±2 37±3
DCT 75±4 69±8 64±7 67±4
CCD 31±2 34±2 35±4 41±5
MCD 31±5 29±3 33±2 38±5
Mg-A TPase activity in nephron segments of HCTZ treated
and control rats.
There was no significant difference in Mg-ATPase activity in
the PCT, PST, MTAL, CTAL, DCT, CCD and MCD between
control and HCTZ-treated animals, and between SHR or WKY
strains (Table 3).
Table 4. Significant group differences
Na-K-ATPase
activity/mm tubule in
MTAL
Group UNa and
comparison BP PNa V Cr PCT CTAL DCT CCD
I. Control SHR vs.
control WKY — C — — C C —
2. HCTZ treated
SHR vs. control
SHR . . — C C C C C
3. HCTZ treated
WKY vs.
control WKY — — — — — — C C
4. HCTZ treated
SHR vs. HCTZ
treated WKY — — C — — C C C
Symbols are: C higher; C lower; — no difference.
Discussion
The experiments described in the present study were de-
signed: 1) to determine if prevention of hypertension in SHR by
HCTZ treatment abolishes the abnormal pattern of Na-K-
ATPase activity along the nephron; and 2) to determine the
effects of HCTZ treatment on Na-K-ATPase activity in nephron
segments of normotensive (WKY) control rats. The studies
were conducted in five—week—old SHR and age matched WKY
and the animals were treated with HCTZ for one week. The
study provides the following major findings: 1) treatment of
SHR with HCTZ decreased Na-K-ATPase activity in PCT,
MTAL, CTAL, DCT and CCD and abolished the abnormal
pattern of the enzyme activity in the PCT but not in other
segments (Table 4); 2) the decrease in Na-K-ATPase activity in
nephron segments of SHR was accompanied by a significant
decrease in BP, Cr and plasma Na concentration; and 3)
treatment of WKY with HCTZ decreased Na-K-ATPase activ-
ity in the DCT, increased the enzyme activity in the CCD and
produced no change in the enzyme activity in PCT, PST,
MTAL, CTAL and MCD.
Recently, we have reported that Na-K-ATPase activity was
higher in the proximal segments (PCT and PST) and lower in the
loop segments (MTAL and CTAL) in five—week-old SHR than
in age matched WKY [1]. In the present study, we have
demonstrated that HCTZ treatment of the animals abolished the
difference in Na-K-ATPase activity in the proximal segments
between SHR and WKY by decreasing the enzyme activity in
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Fig. 1. Na-K-A TPase activity in nephron segments of control (LI) and
HCTZ treated SHR (ff) and WKY (1). Each bar represents mean SE
of number of animals given at the bottom of the bar. *significantly
different (P < 0.05) from control animals of same strain.
Table 3. Mg-ATPase activity in nephron segments of control and
HCTZ treated rats
PCT PST MTAL CTAL DCT CCD MCD
The enzyme activity in mean
min' mm'. The number of animals in
given in Figure 1.
SE expressed as pmol
each group is the same as
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these segments in SHR but not in WKY (Fig. 1). HCTZ has not
been shown to inhibit Na-K-ATPase directly, but is known to
produce a small decrease in extracellular volume and negative
sodium balance. Therefore, the decrease in Na-K-ATPase
activity in the PCT in HCTZ treated SHR is probably due to a
decrease in filtered Na load rather than a direct effect of the
drug on Na reabsorption in this segment. The decrease in
plasma Na and Ccr in HCTZ-treated SHR as compared with
control SHR is consistent with this concept.
HCTZ treatment also decreased Na-K-ATPase activity in the
MTAL and CTAL in SHR but not in WKY (Fig. 1). As we
demonstrated previously [1] and have confirmed in this study,
Na-K-ATPase activity in the MTAL and CTAL was already
lower in control SHR than in control WKY. Therefore, the
differences in Na-K-ATPase activity in the MTAL and CTAL
between HCTZ treated SHR and WKY were of even greater
magnitude than between control SHR and WKY groups. The
reason for the decrease in Na-K-ATPase activity in MTAL and
CTAL with HCTZ treatment of SHR is not known but may be
due to a significant decrease in CCr.
HCTZ treatment decreased Na-K-ATPase activity in the
DCT in both SHR and WKY (Fig. 1). The decrease in Na-K-
ATPase activity in the DCT in SHR may be due to a decrease
in CCr or an effect of the drug in this segment. However, there
were no differences in CCr between HCTZ treated and control
WKY values. Therefore, the decrease in Na-K-ATPase activity
in the DCT is probably not due to any change in Na load in the
DCT in WKY.
The treatment of SHR with HCTZ produced a decrease in
Na-K-ATPase activity in the CCD. HCTZ has been shown to
have no effect on Na transport in the late DCT [61 which
includes initial CCD. Therefore, the decrease in Na-K-ATPase
activity in the CCD by HCTZ treatment of SHR is probably not
due to an effect of the drug on this nephron segment. Further-
more, HCTZ treatment of SHR produced a decrease in Na-K-
ATPase activity in PCT, MTAL and CTAL, none of which has
been shown to be the site of action of HCTZ. In fact, large
concentrations of benzothiazides have been shown to have no
effect on NaCl transport in the CTAL [9]. The decrease in
Na-K-ATPase activity in PCT, MTAL, CTAL and CCD is
probably related to a decrease in Ccr in HCTZ treated SHR.
In contrast to SHR, Na-K-ATPase activity in the CCD from
HCTZ treated WKY was higher than from the control WKY
rats. It is unlikely that an increase in Na-K-ATPase activity in
the CCD of WKY is related to a direct effect of HCTZ on this
segment because there is no evidence that HCTZ affects Na
transport in the CCD. It is possible that the increase in
Na-K-ATPase activity in the CCD from HCTZ treated WKY
may be due to an increase in plasma aldosterone. HCTZ
treatment in humans has been shown to produce aldosteronism
[10] and an increase in plasma aldosterone has been shown to
stimulate Na-K-ATPase activity selectivity in the CCD from the
rabbit [7]. We did not determine plasma aldosterone levels in
our animals. However, the lack of increase in Na-K-ATPase
activity from HCTZ treated SHR argues against the hypothesis
that the increase in Na-K-ATPase activity in the CCD from
HCTZ treated WKY is due to an increase in plasma aldoster-
one. Therefore, it is more likely that an increase in NaC1 load in
the CCD (produced by decreased Na transport in the DCT by
HCTZ) is responsible for the increased Na-K-ATPase activity
in this segment in WKY. This hypothesis is consistent with the
physiological studies in which it has been shown that the
luminal fluid flow rate and its composition can regulate electro-
lyte transport in the initial CCD [11].
Our results of an increase in Na-K-ATPase activity in the
CCD with HCTZ treatment of WKY are also consistent with
those of El Mernissi and Doucet [12] who reported an increase
in Na-K-ATPase activity in the CCD after chronic treatment of
rats with furosemide. Furthermore, the increase in Na-K-
ATPase activity in the CCD was greater than 100% with
furosemide treatment [12] as compared with 50% increase in
Na-K-ATPase activity in this segment with HCTZ treatment in
this study. This may be related to a greater fluid delivery to the
CCD by furosemide than by HCTZ. These results when taken
together are consistent with the hypothesis that Na-K-ATPase
activity in the CCD can be stimulated by an increased Na load
produced by diuretics which inhibit Na transport in segment(s)
proximal to the CCD.
An acute administration of benzothiazides is known to de-
crease CCr. However, CCr is usually unaffected with chronic
administration of diuretics [13]. In this study, there was no
significant difference in CCr between HCTZ treated WKY and
control WKY. Therefore, the decrease in CCr after HCTZ
treatment of SHR is peculiar to this rat strain. The reason for
the lower CCr in SHR treated with HCTZ than in control
animals is not known.
In summary, we have demonstrated that treatment of
normotensive (WKY) rats with HCTZ for one week produced a
decrease in Na-K-ATPase activity in the DCT and an increase
in the enzyme activity in the CCD. These results suggest that
during chronic HCTZ therapy Na reabsorption remains sup-
pressed in the DCT, the site of the drug action, and renal
compensation occurs by an increase in Na reabsorption in the
CCD. The lack of HCTZ effect on Na-K-ATPase activity in
other segments (such PCT, PST, MTAL and CTAL) of WKY
indicates that the drug does not produce a generalized effect on
Na reabsorption along the nephron. The decrease in Na-K-
ATPase activity in almost all the nephron segments of SHR
may, therefore, be related to a decrease in Ccr produced by
HCTZ.
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